DOX. The triplex assay accurately detected efflux pump upregulation between isogenic 23 pairs, which corresponded with decreased antibiotic susceptibility. We further verified 24 assay performance on eight laboratory-generated B. pseudomallei mutants encoding 25 efflux pump regulator mutations. Targeting antibiotic resistance in B. pseudomallei 26 using molecular genotyping provides clinicians with a rapid tool to identify potential 27 treatment failure in near real-time, enabling informed alteration of treatment during 28 an infection and improved patient outcomes. 29 
IMPORTANCE
The melioidosis bacterium Burkholderia pseudomallei is intrinsically re- 30 sistant to many antibiotics, limiting treatment options to a handful of drugs including 31 meropenem, doxycycline and trimethoprim-sulfamethoxazole. Although rare, there 32 have now been several documented melioidosis cases where resistance to these an- 33 tibiotics has developed during an infection, leading to treatment failure and increased 34 mortality rates. Interestingly, all strains resistant to these drugs exhibit increased efflux 35 pump expression, representing a shared molecular signature that can be exploited for 36 rapid diagnostic purposes. Here, we developed and validated a single-tube real-time 37 qPCR assay to detect clinically relevant efflux pump upregulation in B. pseudomallei, an 38 important first step towards high-level resistance. This triplex assay offers a drastically 39 reduced turn-around-time compared to current methodology, enabling earlier detec- 40 tion of resistance emergence. Implementation of this new diagnostic will aid clinicians 41 in the selection of appropriate therapy, thereby minimizing resistance development 46 The development of antibiotic resistance in Gram-negative bacteria has become a global crisis as declared by the World Health Organization (1) and Centers for Disease Next, the linearity of these assays was determined in the triplex and singleplex 126 format. Efficiency (linearity) was measured by the rate at which a PCR amplicon 127 is generated (30) , where the maximum quantitative accuracy occurs in assays that 
INTRODUCTION

141
Comparative genomic analysis identifies a novel amrR mutation in the latter 142 P1048 isolate. SPANDx analysis of MSHR9766 and MSHR9872 was carried out to 143 identify the genetic basis for decreased MEM susceptibility in the latter isolate. Two 144 missense mutations were detected in MSHR9872: a mutation in AmrR (AmrR G50E ), 145 and a mutation in the isoleucine tRNA synthetase gene, ileS (BPSL0906; IleS H505G ), the 146 product of which catalyzes the aminoacylation of Ile-tRNA. In addition, we detected 147 a frameshift mutation in MSHR9872 within BPSS2161 (BPSS2161 A28fs ), which encodes 
152
The triplex qPCR assay was tested on eight clinical B. pseudomallei isolates that encom-153 passed amrR, bpeR or bpeT mutants, including MSHR0052 AmrR E190* , which lacks an 154 isogenic pair. None of the clinical strains tested in our study encoded bpeS mutations. 155 The triplex assay showed increased efflux expression in at least one of the RND efflux 156 pumps in those isolates containing amrR, bpeR or bpeT regulatory mutations ( Figure 2 ), consistent with their role in locally coordinating efflux pump expression. The lat-158 ter strain from P215, MSHR0937, which encodes a mutation within the bpeAB-oprB 159 regulator, bpeR (BpeR D176A ), had a corresponding increase in the expression of bpeB 160 (15x; 3.8-fold; Figure 2A ) compared with its WT isogenic pair, MSHR0664. Similarly, the 161 latter strain isolated from Patient CF6, MSHR5654, which encodes a mutation within 162 the bpeEF-oprC regulator, bpeT (BpeT T314fs ), showed significant upregulation of bpeF 163 (9.5x; 3.2-fold) when compared with its WT isogenic pair, MSHR5651 ( Figure 2B ). 164 Six latter strains, all of which exhibited decreased susceptibility towards MEM ( AmrR ∆ V60-C63 , showed no significant increase in amrB expression. Importantly, the 172 amplification of the triplex assay for all the isogenic strains was within the LoQ of the 173 triplex assay, ruling this factor out as a cause for the lack of differential expression. 
187
Increased efflux expression in laboratory-generated efflux regulator mutants.
188
The triplex qPCR assay was tested on eight laboratory-generated Bp82 mutants con- Given the large number of mutations that can cause RND efflux pump upregu-242 lation (17, 22, 23, 28, 43) , we opted for a multiplex probe-based assay format that 243 identifies increased gene expression in favor of designing individual assays targeting 244 each regulatory mutation, the latter of which would be both impractical (due to the 245 large number of assays required) and prone to false negatives (due to the high likeli-246 hood of missing novel variants). In addition, detecting RNA expression ensures that 247 efflux pump upregulation is identified without requiring a thorough understanding 248 of the underlying regulatory networks. We first optimized the three highly specific 249 efflux pump qPCR assays in both the singleplex and triplex formats, with all assays 250 demonstrating high robustness and sensitivity levels, similar to the highly robust B.
251
pseudomallei mmsA probe-based assay (31) . folM/ptr1, are required for the shift towards high-level DOX and SXT resistance (23, 24) . 268 The two-step nature of these mechanisms means that the triplex qPCR assay alone 269 cannot be used to definitively determine if a strain is resistant to DOX or SXT. However, 270 the assay can be used to rule out antibiotic resistance, as a strain with little or no 271 efflux activity is highly likely to be sensitive to these drugs. Importantly, the ability 272 to rapidly screen isolates and detect precursor mutations to clinically relevant DOX 273 and SXT resistance provides a unique opportunity for health practitioners to make 274 informed decisions regarding the suitability of current treatment, and to be aware of is that RND efflux pump regulatory genes are capable of binding to substrates of the 291 efflux systems that they regulate, and in doing so, dissociate from their promoter 292 regions, leading to efflux pump upregulation (44, 45) . This hypothesis may explain 293 the molecular mechanism in the strains that encode the in-frame amrR deletions. 294 However, this concept cannot be applied to the strain lacking amrR, as the regulator is 295 not present, which would lead to efflux pump expression even in the absence of MEM.
296
Although not examined in this study, it is possible that a second, as-yet-undiscovered 297 regulator may also be involved in amrAB-oprA regulation. Alternately, certain mutation were created via site-directed mutagenesis and knockouts to investigate the mecha-400 nisms of SXT resistance in B. pseudomallei using previously described methods (24) . Bp82.280 ∆(amrAB-oprA) ∆bpeR was derived from a previously created strain (Bp82.27) 402 as previously described (27, 56) of amrR was amplified by PCR (using Bp82 genomic DNA as template) using primers 412 amrR_UP_F, amrR_UP_R, amrR_DN_F and amrR_DN_R ( Table 3 ). The PCR fragments 413 were purified and assembled into pEXKm5 to create pEXKm5-US-DS-amrR (Table 2) , 414 using NEBuilder High-Fidelity DNA Assembly system (New England Biolabs, Ipswich,
MATERIALS AND METHODS
415
MA, USA). pEXKm5-US-DS-amrR was subsequently conjugated into Bp82 using an E.
416
coli RHO3 mobilizer strain (51) . Finally, merodiploids were selected for and resolved.
417
The resultant ∆amrR strain was named Bp82.410. Loss of amrR was confirmed by PCR 418 amplification using the primers amrR_Fullgene_F and amrR_Fullgene_R (Table 3) (Table 2 ) using primers amrR_Fullgene_F and amrR_Fullgene_R 424 (Table 3) . Site-directed mutagenesis was performed using pGEM-T-US-DS-WT-amrR 425 together with the amrR mutagenic primers amrR_T520C_F and amrR_T520C_R (Table 3) 426 to create pGEM-T-US-DS-amrRT520C ( Bp82 mutants, a 23S rDNA assay was also used as described elsewhere (27 
